Market Intelligence, Early Discovery Trends, and High-Purity Reagents for Transcription Factor-Targeted Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ZBTB11 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length) | ZBTB11 FL Recombinant Protein. HEK293 expressed, dual tag (His/GST), endotoxin <0.1 EU/μg, theoretical MW verified. | View ZBTB11 Products |
| Antigen (BTB Domain) | ZBTB11 BTB/POZ Domain (1-130 aa). High solubility for PPI studies, purity >95%, sequence verified. | View ZBTB11 Products |
| Antigen (Zinc Finger Array) | ZBTB11 Zinc Finger Domain. Native folding confirmed, suitable for EMSA/SPR DNA-binding assays. | View ZBTB11 Products |
| Gene Delivery | ZBTB11 Promise-ORF Lentivirus. Full-length ORF for stable nuclear expression, puromycin selection. | View ZBTB11 Products |
| Benchmark Ab | Anti-ZBTB11 Recombinant Antibody. Positive control for Western, IP, and ChIP normalization, strictly sequence verified. | View ZBTB11 Products |
| Validator | ZBTB11 siRNA Set (3 unique sequences). For knockdown verification and specificity checks. | View ZBTB11 Products |
| Related Target A | CUL3 – Core E3 ubiquitin ligase scaffold; context for BTB-adaptor complex biology. | View CUL3 Products |
| Related Target B | BCL6 – Established BTB-family transcription factor; structural paralog for selectivity assays. | View BCL6 Products |
| Related Target C | ZBTB7A (Pokemon) – Oncogenic paralog, frequently co-deregulated in hematological malignancies. | View ZBTB7A Products |
| Related Target D | CRBN – Essential E3 ligase partner for PROTAC / Targeted Protein Degradation. | View CRBN Products |
| Related Target E | VHL – Alternative E3 ligase core component for degrader design. | View VHL Products |
| Related Target F | ZBTB33 (Kaiso) – BTB-ZF family member, alternative epigenetic reader for combination screening. | View ZBTB33 Products |
| Related Target G | KDM1A (LSD1) – Epigenetic partner protein, reported functional interaction with ZBTB11 in chromatin remodeling. | View KDM1A Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nuclear Protein Solubility & Stability | HEK293 expression system with optimized codons; low endotoxin (<0.1 EU/μg) prevents cellular toxicity in prolonged nuclear assays. |
| BTB Domain Dimerization/Oligomerization | Full-length and BTB-domain truncations available with validated oligomeric status (SEC-MALS compatible). |
| DNA Binding Specificity (Off-target) | Zinc Finger Domain proteins with confirmed conformation; suitable for EMSA and FP-based specificity profiling. |
| Ternary Complex Formation (PROTAC) | High purity (>95%) intracellular proteins suitable for SPR/BLI binding assays. |
| Transient vs. Stable Expression Variability | Matched Lentivirus and siRNA from same sequence source ensures assay consistency across transient and stable models. |
| Lack of Structural Controls | Domain-specific constructs (BTB vs. ZF) serve as internal controls for mapping interaction interfaces. |
| Lack of Reliable Controls | Sequence-verified recombinant positive control antibodies included. |
| False Positive Knockdown | Validated siRNA included for precise intracellular specificity checks. |
| Subfamily Selectivity & Off-target Risk | Ortholog and paralog panels (Human ZBTB11, BCL6, ZBTB7A); sequence verified by mass spec. |
| Full-length Cellular Functional Assays | Promise-ORF Lentivirus for stable nuclear expression; HEK293 system, endotoxin controlled. |
LIVE ZBTB11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
ZBTB11 (zinc finger and BTB domain-containing protein 11) is an intracellular transcription factor belonging to the BTB-ZF family. It functions as a sequence-specific DNA-binding transcriptional repressor implicated in hematological malignancies, solid tumors, and DNA damage responses. The protein contains an N-terminal BTB/POZ domain mediating dimerization and protein-protein interactions, and a C-terminal zinc finger array for DNA recognition. Key mutations include rs3749323, rs33957144, and rs1559982532 (NEDMCB syndrome, impaired nucleolar localization).
The current R&D landscape is dominated by early discovery and preclinical efforts. Traditional small molecule inhibitors struggle due to the lack of deep binding pockets typical of transcription factors. Instead, strategies are shifting toward Targeted Protein Degradation (TPD) via molecular glues and PROTACs, as well as RNA interference and protein-protein interaction (PPI) inhibitors targeting the BTB domain. Epigenetic combinations (e.g., with KDM1A or HDAC inhibitors) are also being explored. The competitive space is fragmented but intensifying, with academic labs and early-stage biotechs leading innovation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Targeted Protein Degradation (PROTAC / Molecular Glue) | Preclinical Biotech Innovators | Acute Myeloid Leukemia (AML), Solid Tumors | Ternary complex binding – need high-purity recombinant ZBTB11 & E3 ligases (CRBN, VHL). |
| Small Molecule PPI Inhibitor | Emerging Academic Labs | AML, Hematological Cancers | BTB domain dimerization assay – need high-purity BTB domain with confirmed oligomeric state. |
| Nucleic Acid Therapeutics (RNAi / ASO) | Nucleic Acid Companies | Oncology, Genetic Disorders | Knockdown validation – need sequence-verified ORF and siRNA sets. |
| Epigenetic Combination | Oncology Pharma | Gastric Cancer, AML | Co-IP grade antigens – need interaction partners (e.g., KDM1A) for mechanistic studies. |
| Allosteric / DNA-Binding Disruptor | Early Drug Discovery Programs | Solid Tumors | EMSA & reporter assays – need mutant vs WT zinc finger proteins. |
| Stapled Peptides | Biotech Startups | Hematological Malignancies | Zinc Finger domain – need properly folded ZF for DNA competition binding assays. |
Key Variations & Assay Controls
ZBTB11 has several documented genetic variants that serve as important assay controls:
- rs3749323: Sequence variant (UniProt VAR_021894).
- rs33957144: Sequence variant (UniProt VAR_047465).
- rs1559982532: Associated with NEDMCB syndrome; impairs localization to the nucleolus (UniProt VAR_082098).
TarMart offers mutant recombinant proteins (BTB domain or full-length) bearing these specific substitutions for use as negative controls in binding assays, cellular localization studies, and degrader specificity profiling.